Notizie AIOM – anno XIV n. 574

15 Marzo 2016

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer

The US Preventive Services Task Force recently recommended the use of aspirin to prevent colorectal cancer and cardiovascular disease among many US adults. However, the association of aspirin use with the risk for other cancer types and the potential population-wide effect ...
Leggi tutto

15 Marzo 2016

11 marzo 2016 – FDA approva crizotinib per il NSCLC metastatico ROS1-positivo

11 Marzo 2016

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

In metastatic breast cancer, nab-paclitaxel has been shown to significantly increase progression-free survival compared with solvent-based paclitaxel. The GeparSepto (GBG 69) trial assessed whether weekly nab-paclitaxel could increase the proportion of patients achieving ...
Leggi tutto

11 Marzo 2016

8 marzo 2016 – Regimi di fornitura e prescrittori per i medicinali a base di imatinib e cinacalcet

11 Marzo 2016

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

Fluorouracil plus leucovorin (FU + LV) adjuvant chemotherapy reduced the risk of recurrence and death across all time points in a pooled analysis of 20,898 patients with colon cancer from 18 randomized studies. The impact of oxaliplatin added to FU + LV on the time course ...
Leggi tutto

11 Marzo 2016

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

This trial assessed the efficacy and safety of docetaxel monotherapy or docetaxel in combination with ramucirumab (vascular endothelial growth factor receptor 2 antibody) or icrucumab (vascular endothelial growth factor receptor 1 antibody) after progression during or within ...
Leggi tutto

11 Marzo 2016

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

Comprehensive geriatric assessment (CGA) is recommended to assess the vulnerability of elderly patients, but its integration in cancer treatment decision making has never been prospectively evaluated. Here, in elderly patients with advanced non–small-cell lung cancer ...
Leggi tutto

11 Marzo 2016

10 marzo 2016 – Aspirina per la prevenzione del cancro: uno studio ne rivela i potenziali effetti positivi

11 Marzo 2016

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

Immunostimulatory monoclonal antibodies (imAbs) targeting immune checkpoint molecules are revolutionizing oncology not only regarding cancer therapeutics and clinical care, but also from a drug development point of view. A handful of first-generation molecules have been ...
Leggi tutto

11 Marzo 2016

7 marzo 2016 – AIFA: Nota Informativa Importante sull’aggiornamento degli stampati dei medicinali a base di amoxicillina/acido clavulanico

LAVORIAMO CON

News

TUMORE SENO, QUALITA’ DI VITA “FATICOSA MA SODDISFACENTE” PER 4 PAZIENTI SU 10

I dati di follow-up a lungo termine dello studio di fase 3 con mavacamten sottolineano il profilo consolidato di efficacia e sicurezza nei pazienti con cardiomiopatia ipertrofica

BEIGENE ITALIA: ILARIA PIUZZI NUOVO DIRETTORE PUBLIC AFFAIRS, COMUNICAZIONE E PATIENT ADVOCACY

TUMORI: 22 BARCHE A CAPRERA PER IL PROGETTO “PAZIENTI A BORDO”

IN ITALIA 1,7 MILIONI DI PERSONE COLPITE DA MAL DI SCHIENA INFIAMMATORIO

LISTE D’ATTESA, SEBASTIANI (SIR): “PRIMI IMPORTANTI RISULTATI. ORA LO SPECIALISTA REUMATOLOGO”

Alcol, più donne consumatrici e 15% giovani ama il binge drinking

Notizie AIOM – anno XIV n. 574

Population-wide Impact of Long-term Use of Aspirin and the Risk for Cancer

11 marzo 2016 – FDA approva crizotinib per il NSCLC metastatico ROS1-positivo

Nab-paclitaxel versus solvent-based paclitaxel in neoadjuvant chemotherapy for early breast cancer (GeparSepto-GBG 69): a randomised, phase 3 trial

8 marzo 2016 – Regimi di fornitura e prescrittori per i medicinali a base di imatinib e cinacalcet

Impact of Patient Factors on Recurrence Risk and Time Dependency of Oxaliplatin Benefit in Patients With Colon Cancer: Analysis From Modern-Era Adjuvant Studies in the Adjuvant Colon Cancer End Points (ACCENT) Database

Docetaxel As Monotherapy or Combined With Ramucirumab or Icrucumab in Second-Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma: An Open-Label, Three-Arm, Randomized Controlled Phase II Trial

Use of a Comprehensive Geriatric Assessment for the Management of Elderly Patients With Advanced Non–Small-Cell Lung Cancer: The Phase III Randomized ESOGIA-GFPC-GECP 08-02 Study

10 marzo 2016 – Aspirina per la prevenzione del cancro: uno studio ne rivela i potenziali effetti positivi

Challenges of phase 1 clinical trials evaluating immune checkpoint-targeted antibodies

7 marzo 2016 – AIFA: Nota Informativa Importante sull’aggiornamento degli stampati dei medicinali a base di amoxicillina/acido clavulanico